A UPMC report says that while many health systems now offer precision medicine programs, scaling remains constrained by reimbursement, data integration, and patient engagement. The findings argue that genomics must be embedded into routine care while programs demonstrate both clinical and financial value. The report frames execution as the central bottleneck—moving beyond pilot activities toward operational workflows that can handle testing, interpretation, and follow-up at scale. It also highlights that patient engagement and reimbursement structures can determine whether precision programs translate into measurable outcomes. The industry takeaway is practical: even with advances in sequencing and interpretation, health-system adoption will depend on integration into care pathways and proof of downstream impact.